Cambridge Cardiac Care Centre

Our Research Studies

Want to enrol in a clinical trial?

Participating in a clinical research study provides exciting opportunities to be a part of history in the making as well as providing unique access to novel technologies and therapies that are not otherwise available to patients at large. It does, however, require thoughtful consideration. Talk with your doctor and family members before deciding to enrol. Either you or your doctor may contact our research staff for more information and to discuss any studies that may be suitable for you specifically.

Wave graphic DSC 6770 Version 2

ASPIRE-AF study

The ASPIRE-AF study is a Phase 4 clinical trial evaluating whether an investigational use of standard non-vitamin K oral anticoagulants (blood thinners) can safely and effectively reduce the risk of strokes and other vascular complications. This study focuses on adults who have recently experienced a brief, temporary episode of…

Wave graphic 074810

AZURE-Outcomes study

The AZURE-Outcomes study is a Phase 3 clinical trial evaluating whether an investigational oral medication called AZD0780, an oral PCSK9 inhibitor, can reduce the risk of major cardiovascular events like heart attacks and strokes. This study focuses on adults who have established cardiovascular disease, or who are at high risk for a first…

Wave graphic P1060890

dal-GenE-2

The dal-GenE-2 study is a Phase 3 clinical trial evaluating whether an investigational medication called dalcetrapib can reduce the risk of future heart attacks or strokes. This precision medicine study focuses on adults aged 45 and older who were recently hospitalized for acute coronary syndrome or a heart attack within the past…

Wave graphic Pexels anna shvets 3844581

EASi-HF Preserved study

 
The EASi-HF Preserved study is a Phase 3 clinical trial evaluating whether combining an investigational medication called vicadrostat with an approved heart failure medication, empagliflozin, can reduce the risk of cardiovascular death or hospitalization. This study focuses on…
Wave graphic P1060890

FINE-MECH study

The FINE-MECH study is a Phase 3 clinical trial evaluating whether an investigational medication called finerenone can improve heart structure and function in individuals at risk for cardiac and renal disease who have heart muscle thickening (left ventricular hypertrophy- LVH). This ventricular remodeling study focuses on adults…

Wave graphic Katie at computer with treadmill in shot

LAAOS-4 study

The LAAOS-4 study is a Phase 4 clinical trial evaluating whether using a catheter-delivered device called the WATCHMAN FLX to close off the heart's left atrial appendage can provide extra protection against strokes and blood clots. This study focuses on adults aged 18 and older with atrial fibrillation who remain at a high risk for…

Wave graphic DSC 6770 Version 2

Lp(a)FRONTIERS CAVS study

The Lp(a)FRONTIERS CAVS study is a Phase 2 clinical trial evaluating whether an investigational medication called pelacarsen can slow the progression of calcific aortic valve stenosis in patients with mild to moderate aortic stenosis and elevated Lp(a). This study focuses on adults aged 50 to 79 who have been diagnosed with mild or…

Wave graphic Technician at monitor

MARITIME-HF study

The MARITIME-HF study is a Phase 3 clinical trial evaluating whether an investigational medication called maridebart cafraglutide can reduce heart failure symptoms and the risk of related hospitalizations. This study focuses on adults aged 18 and older who are living with both chronic heart failure and obesity. Eligible…

Wave graphic P1010791

Ocean (a) Pre-EVENT

The OCEAN(a)-PreEvent study is a Phase 3 clinical trial evaluating whether an investigational medication called olpasiran can prevent first-time heart attacks or strokes in patients with elevated Lp(a). The study focuses on adults aged 50 and older who have high levels of lipoprotein(a) [Lp(a)]—a genetically inherited form of cholesterol that…

Wave graphic 074810

SOS-AMI study

The SOS-AMI study is a Phase 3 clinical trial evaluating whether an investigational medication called selatogrel can reduce the risk of severe complications or death during a recurrent heart attack. This trial focuses on adults aged 18 and older who have experienced a heart attack within the past four weeks and carry additional…

Wave graphic P1060890

ATHENA study

The ATHENA study is a Phase 3 clinical trial evaluating whether an investigational medication called ziltivekimab can improve symptoms and quality of life for individuals living with heart failure and systemic inflammation. This study focuses on adults with heart failure who have a mildly reduced or preserved left…
Wave graphic 074939

AZURE-LDL study

The AZURE-LDL study is a Phase 3 clinical trial evaluating whether an investigational oral medication called AZD0780 can safely and effectively lower low-density lipoprotein cholesterol (LDL-C), commonly known as bad cholesterol. This study focuses on adults aged 18 and older who have established cardiovascular disease, or who are at a high…

Wave graphic P1070005

CORALreef Outcomes (MK-0616-015): oral PCSK9 Inhibitor in refractory hyperlipidemia and cardiovascular events

Assessing MK-0616, an oral PCSK9 inhibitor, in participants with high cardiovascular risk and LDL cholesterol refractory to Statins on major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial…

Wave graphic P1080068

HERMES: Ziltivekimab in People With Heart Failure and Inflammation

Ziltivekimab is a human monoclonal antibody that works by reducing inflammatory responses within the body. Ziltivekimab has the potential to reduce inflammation in patients with HF, and consequently may reduce symptoms, as well as long-term morbidity and mortality. Participants will receive ziltivekimab 15 milligrams (mg) subcutaneous (s.c.)…

Wave graphic P1060888

MARITIME-CV study

The MARITIME-CV study is a Phase 3 clinical trial evaluating whether an investigational medication called maridebart cafraglutide can reduce the risk of serious heart events, such as heart attacks, strokes, or cardiovascular death. This trial focuses on adults aged 45 and older who live with established atherosclerotic…

Wave graphic P1060889

OCEAN(a) - Outcomes Trial: Effects of Olpasiran To reduce Lipoprotein (a) and impact on Cardiovascular Events

The primary objective of this study is to compare the effect of treatment with olpasiran on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

Wave graphic Pexels pixabay 139398

Redefine: Effects of CagriSema in People Living With Obesity and Diseases in the Heart and Blood Vessels

You may be able to take part if:

  • You have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral arterial disease, or PAD)
  • You are 55 years of age or older
  • You are living with obesity (BMI over 30)

  • (OSLER)Amgen

  • Accelerate

  • Active (A & I)

  • AIM HIGH

  • AKCEA

  • Alecardio

  • AlePrevent

  • ALOFT

  • Altitude

  • Amgen (Decartes)

  • Amgen (OSLER II )

  • Amgen Phase III (La Place II)

  • APPRAISE 2

  • Arise -Focus

  • Aristotle

  • Armada Registry

  • Assert II

  • Astronomer

  • ATLAS

  • Atmosphere

  • Averroes

  • Aware AF Program

  • Bax24 study

    The Bax24 study is a Phase 3 clinical trial evaluating whether an investigational oral medication called baxdrostat can safely and effectively lower blood pressure around the clock in individuals with resistant hypertension. This study focuses on adults aged 18 and older whose blood pressure remains high despite taking at least three different blood pressure medications, including a diuretic. Participants receive a once-daily tablet containing either the study medication or a placebo for approximately 12 weeks as an addition to their standard treatments. Throughout the trial, participants undergo regular clinic visits, laboratory evaluations, and continuous 24-hour ambulatory blood pressure monitoring to allow our clinical research team to track day and night blood pressure changes.

  • BaxHTN study

    The BaxHTN study is a Phase 3 clinical trial evaluating whether an investigational oral medication called baxdrostat can safely and effectively lower blood pressure in individuals with hard-to-control hypertension. This study focuses on adults whose blood pressure remains high despite taking multiple background blood pressure medications, including individuals with uncontrolled hypertension on two therapies or resistant hypertension on three or more medications. Participants receive a once-daily tablet containing either the study medication or a placebo for approximately 12 weeks as an addition to their standard blood pressure treatments. Throughout the trial, participants undergo regular clinic visits, laboratory evaluations, and continuous health monitoring from our clinical research team.

  • Beautiful

  • BEST

  • BP EASE

  • BRAIN AF: Treating the heart, Helping the brain

    A study involving patients with Atrial Fibrillation and a CHADS2 score of 0. with a goal of reducing stroke, transient ischemic attack (TIA) and neurocognitive decline. To participate in this study, you must: Have a diagnosis of atrial fibrillation; Be between 30 and 62 years old; Absence of arterial hypertension; diabetes, stroke or heart failure

  • CAIN

  • Camellia TIMI 61

  • CANTOS OLE

  • Cardurion 201 study

    The Cardurion 201 study is a Phase 2 clinical trial evaluating whether an investigational oral medication called tovinontrine can safely and effectively improve cardiac health in individuals with heart failure. This study focuses on adults living with chronic heart failure with reduced ejection fraction, a condition where the heart muscle is weakened and struggles to pump enough blood to the rest of the body. Participants receive a twice-daily tablet containing either the study medication or a placebo as an addition to their standard, guideline-directed heart failure treatments. Throughout the trial, participants undergo regular clinic visits, laboratory evaluations, and continuous health monitoring from our clinical research team.

  • Cardurion 202 study (Cycle-2-PEF trial)

    The Cardurion 202 study (also known as the Cycle-2-PEF trial) is a Phase 2 clinical trial evaluating whether an investigational oral medication called tovinontrine can safely and effectively improve cardiac health in individuals with heart failure. This study focuses on adults living with chronic heart failure with preserved ejection fraction, a condition where the heart muscles contract normally but the heart chambers are stiff and struggle to fill with enough blood. Participants receive a daily tablet containing either the study medication or a placebo for approximately 12 weeks as an addition to their stable, standard heart failure treatments. Throughout the trial, participants undergo regular clinic visits, laboratory evaluations, and continuous health monitoring from our clinical research team.

  • Carolina

  • Clarify Registry

  • Class Act

  • Cogentus

  • Cogentus con…

  • Commander

  • COMPASS LTOLE

  • Confidence 2

  • CTAF-2

  • CV Mobius Registry

  • CVEA 2303 **

  • Dal Outcomes Roche

  • Dal Plaque 2

  • Dapa HF Outcomes

  • DAR 311/ E

  • DECLARE ( TIMI 58 )

  • DELIGHT

  • DELIVER

    A phase 3 study assessing the impact of Dapagliflozin, an SGLT2 inhibitor, on reduction of cardiovascular events and worsening heart failure in patients with heart failure with preserved ejection fraction. This study is finished enrolling and is in follow-up.

  • DERIVE

  • Discovery

  • DM 71-05-01

  • DYSIS

  • Electra/DRONE

  • Empa Kidney

    A randomized, double-blind, placebo-controlled trial of Empagliflozin in people with chronic kidney disease, with or without diabetes, to assess if Empagliflozin reduces the risk of kidney disease progression or cardiovascular death. This study is finished enrolling and is in follow-up.

  • Emperor HF ( HFrEF )

  • Esperion

    A randomized, double-blind, placebo-controlled study to assess the effects of Bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in statin intolerant patients with, or at high risk of developing, cardiovascular disease. This study is finished enrolling and is in follow-up.

  • Excel

  • Eze(stat) II

  • Ezetrol

  • Finearts

    A study involving HFpEF, Heart Failure patients with an ejection fraction greater than or equal to 40%. This randomized, double-blind, double-dummy, multi-centre Phase 3 clinical trial studies the efficacy and safety of Finerenone, taken once daily. The study monitors effects on symptoms, morbidity and mortality reduction.

  • FOCUS

  • Fourier (AMGEN )

  • FRESH

    A study involving difficult-to-treat or Resistant Hypertension cases. This phase 3, double-blind, placebo-controlled clinical trial studies the efficacy and safety of Firibistat (QGC001) as administered orally, twice daily, over 12 weeks to resistant-hypertension patients.

  • Galactic HF

  • GARFIELD Registry

  • Genetic AF

  • Gloria Registry

  • GOALProgram

  • HAT

  • Heart-Fid

    A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Injectafer® (Ferric Carboxymaltose) as treatment for Heart Failure with iron deficiency. This study is finished enrolling and is in follow-up.

  • HTN-A-Fib PILOT

  • I-Search

  • Improve-IT

  • INVESTED

  • Iris *fininshed**

  • ISH

  • Jupiter

  • LCZ696A 2201 US

  • LTOLE

  • LTS (Oydssey)

  • Mavik (TORY)

  • Merck 162 (Switch)

  • Merck 4448

  • NODE 302 ( open label )

  • NODE 303

    A study involving patients with Paroxysmal Supraventricular Tachycardia (PSVT). Patients with symptomatic heart failure or who have syncope/hypotension with SVT will not be recruited in this case. This multi-centre, open-label, Phase 3 study monitors the safety of Etripamil nasal spray for the termination of PSVT. Monitoring of symptoms is mostly completed remotely via an app on a mobile device.

  • Oberon/ Obelix

  • OCEANIC-AF: Asundexian Compared to Apixaban to Prevent Stroke or Systemic Embolism in Atrial Fibrillation

    Asundexian belongs to an emerging class of medicines known as factor XIa inhibitors, which are viewed as potentially safer and more effective alternatives to new oral anticoagulants (NOACs). Factor XI is a protein in the blood that is converted into its active enzyme form (factor XIa) as part of the blood coagulation cascade. Inhibiting factor XI offers an attractive strategy for stroke prevention as it reduces the formation of pathologic thrombi, while preserving the ability to form clots in response to bleeding. This contrasts with the currently used NOACs such as Eliquis (apixaban) and Xarelto (rivaroxaban), which inhibit factor Xa and consequently reduce the body’s ability to form clots. By selectively modulating coagulation, factor XIa inhibitors such as asundexian have the potential to prevent thromboembolic events without increasing the risk of bleeding like the current standard of care.

  • Odysseus

  • Odyssey Outcomes

  • PACT

  • Pallas

  • Pandora LCZ-

  • Paradigm

  • Paragon

  • PARASAIL

  • Pegasus -TIMI 54

  • PNAI_MNA_001

  • POWER

  • Prominent

    A randomized, double-blind, placebo-controlled, event-driven efficacy and safety study to assess if Pemafibrate reduces cardiovascular outcomes by reducing triglycerides in patients with diabetes. This study is finished enrolling and is in follow-up

  • RAPID NODE 301

    A study involving patients with Paroxysmal Supraventricular Tachycardia (PSVT). Patients with symptomatic heart failure or who have syncope/hypotension with SVT will not be recruited in this case. This double-blind, placebo-controlled, phase 3 trial studies the efficacy and safety of Etripamil Nasal Spray for the termination of PSVT. This study requires a test dose to be admisnisterd in-clinic at randomization to be enrolled.

  • RE-LY

  • Reached

  • React Program

  • Realize-K: Sodium Zirconium Cyclosilicate (SZC) for the management of Hyperkalemia in patients with congestive heart failure

    A study involving patients with symptomatic Heart Failure with reduced Ejection Fraction and Receiving Spironolactonehase IV. This double-blind, placebo-controlled, randomized-withdrawal trial evaluates the use of Sodium Zirconium Cyclosilicate (SZC) for the management of Hyperkalemia in patients with reduced ejection fraction heart failure who develop elevated potassium (K) levels when treated with MRAs.

  • REDEEM

  • REFINE ICD: the use of prophylactic ICD therapy to reduce the risk of sudden cardiac death in patients with LVEF between 36% to 50%

    A study involving heart attack patients who have reduced heart pumping function (LVEF between 36% to 50%). This international, multi-centre trial assesses the use of prophylactic ICD therapy to reduce the risk of sudden cardiac death.

  • REFRESH

    A study involving difficult-to-treat or Resistant Hypertension cases. This phase 3, double-blind, placebo-controlled and open-label clinical trial studies the efficacy and long-term safety of Firibistat (QGC001) as administered orally, once daily.

  • RELY-ABLE

  • REVEAL - TIMI 55

  • Rocket 81408

  • RUBY 1

  • SAALT

  • SELECT

    A phase 3 study assessing the impact of Semaglutide, a GLP1 receptor agonist, on weightloss and the recurrence of cardiovascular events in patients with atherosclerotic cardiovascular disease without diabetes. This study is finished enrolling and is in follow-up.

  • SOLID- TIMI 52

  • Soloist

  • SPIRE 1

  • SPIRE 2

  • STEP HFpEF

    A study involving patients with obesity-related heart failure who have a preserved ejection fraction and do not have diabetes. This phase 3a, randomized, placebo-controlled, double-blinded, multi-centre clinical trial compares Semaglutide with placebo as related to worsening heart failure symptoms and weight loss.

  • STEP HFpEF DM

    A study involving patients with obesity-related heart failure who have a preserved ejection fraction and type 2 diabetes. This phase 3a, randomized, placebo-controlled, double-blinded, multi-centre clinical trial compares Semaglutide with placebo as related to worsening heart failure symptoms and weight loss.

  • Study 112 Elderly

  • Study 79 (Tempo)

  • Study 90 (EZEPATH)

  • Sure Registry (25)

  • SURPASS

    A phase 3 study assessing the effects of Tirzepatide, a GIP and GLP1 receptor agonist, in reducing future cardiovascular events in patients with diabetes and established cardiovascular disease . This study is finished enrolling and is in follow up.

  • SYNCHRONIZE-CVOT, survodutide on Obesity and heart disease risk

    Study of survodutide in people with obesity / overweight with cardiovascular disease, chronic kidney disease or risk factors for heart disease. Inclusion Criteria:-BMI ≥27 kg/m2 with established heart disease and/or at least 2 weight related complications OR -participants with BMI ≥30 kg/m2 with established heart or kidney disease and/or at least 2 weight-related complications

  • TECOS (TIMI)

  • THEMIS

  • Tigris

  • Tigris

  • TIGRIS REGISTRY

  • TRA 2PB

  • Tranquility

  • VERTIS

  • VICTOR: Vericiguat in patients with reduced ejection fraction heart failure

    A study involving adults with chronic Heart Failure with reduced Ejection Fraction. This pivotal phase 3, randomized, placebo-controlled, clinical study evaluates the efficacy and safety of the sGC Stimulator Vericiguat/MK-1242 in patients with reduced ejection fraction heart failure on optimum medical therapy.

  • VICTORIA

  • VICTORIA HF REGISTRY

  • Zerbini Registry